KAIST researchers have developed a way to reprogram immune cells already inside tumors into cancer-killing machines. A drug ...
Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in Jun ...
Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback